Maine Angels to get first return on investment
Maine Angels is expected to get its first-ever return on investment after one of its portfolio companies went public last month.
The Portland Press Herald reported that two members of Maine Angels will soon be in a position to receive a return on their combined $125,000 investment in Massachusetts-based Corbus Pharmaceuticals, though their exact plans are not currently known. One of the Maine Angels investors is John Goodrich, while the other declined to be identified.
A spokeswoman for Corbus Pharmaceuticals, which focuses on developing and commercializing treatments for cystic fibrosis and other diseases, told the Press Herald that investors would be best off not immediately selling their stock when allowed to on Jan. 1, 2015 because of several “value-driving” milestones expected next year.
Maine Angels, which has invested more than $10 million into its portfolio companies since starting in 2003, was named in a report as one of the most active angel investment groups in the country last month. The investment group closed on 14 deals during this year’s second quarter, amounting to nearly $1.3 million, according to the Angel Capital Association's most recent Halo Report, which surveys national angel investment activity.
Read more
Venture capital investments in Maine up for Q2
Most Recent
Most Recent
Comments